对用于癌症管理的斯芬戈辛激酶1抑制剂进行分子对接分析
1Department of Medical Lab Technology, Prince Fahd Bin Sultan Research chair, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
Bioinformation
|October 27, 2023
概括
研究人员确定了四种天然化合物,这些化合物可能会抑制氨酸激酶1 (SK1),这是癌症中过度表达的酶. 这些化合物显示为潜在的抗癌药物,有望进一步研究.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 斯芬戈氨基激酶1 (SK1) 对于细胞生存和增殖至关重要.
- 过度表达SK1与各种癌症的瘤进展有关,使其成为治疗点.
- 鉴定新型SK1抑制剂对于开发新的抗癌疗法至关重要.
研究的目的:
- 通过对自然化合物的虚拟选来识别基酶1 (SK1) 的潜在抑制剂.
- 根据SK1.1,评估已识别的化合物的结合亲和力和特异性.
- 评估潜在的SK1抑制剂的类似药物的特性,以便进一步进行实验验证.
主要方法:
- 对1068种天然化合物的虚拟选与SK1绑定口袋相比.
- 根据结合亲和力和特异性选择最受欢迎的化合物.
- 对所选化合物的药物类似性标准的评估.
主要成果:
- 四种天然化合物 (CNP0296172,CNP0368143,CNP0380570,CNP0290815) 被确定为最受欢迎的药物.
- 这些化合物对SK1结合口袋表现出强烈的结合亲和力和特异性.
- 鉴定出的化合物表现出比阳性对照 (PF-543) 更高的亲和力,并符合类似药物的标准.
结论:
- 已识别的天然化合物是SK1抑制的有希望的候选物.
- 这些化合物需要进一步实验验证作为潜在的抗癌剂.
- 这项研究强调了虚拟查在发现癌症新疗法的有用性.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K